Related Experiment Video

Updated: May 5, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.0K

Interactions of ketoamide inhibitors on HCV NS3/4A protease target: molecular docking studies

Abdul Wadood, Muhammad Riaz, Syed Babar Jamal

    Molecular Biology Reports
    |November 16, 2013
    PubMed

    Insights

    Hepatitis C virus (HCV) ketoamide inhibitors show promise for treating infections. Molecular docking reveals key interactions, guiding the development of more effective NS3/4A protease inhibitors.

    Area of Science:

    • Virology
    • Medicinal Chemistry
    • Computational Biology

    Background:

    • Hepatitis C virus (HCV) infection affects over 200 million people globally.
    • Traditional treatments like pegylated interferon-α and ribavirin have significant side effects, leading to treatment discontinuation.
    • HCV NS3/4A protease inhibitors are emerging as a promising therapeutic strategy.

    Purpose of the Study:

    • To investigate the binding interactions and activity trends of HCV NS3/4A protease ketoamide inhibitors.
    • To utilize molecular docking to understand the structure-activity relationships of these inhibitors.

    Main Methods:

    • Molecular docking studies were performed using the MOE docking protocol.
    • Ketoamide derivatives targeting HCV NS3/4A protease were analyzed.

    Main Results:

    • The molecular docking analysis identified crucial ligand interactions within the NS3/4A protease binding site.
    • A good correlation (r2 = 0.690) was observed between docking scores and biological activities.
    • Key interactions contributing to inhibitor potency were elucidated.

    Conclusions:

    • Molecular docking provides valuable insights into the binding mechanisms of HCV NS3/4A protease inhibitors.
    • The findings support the further optimization of ketoamide derivatives for enhanced antiviral efficacy.
    • This study contributes to the rational design of novel HCV therapeutics.

    More Related Videos

    Use of Viral Entry Assays and Molecular Docking Analysis for the Identification of Antiviral Candidates against Coxsackievirus A1606:03

    Use of Viral Entry Assays and Molecular Docking Analysis for the Identification of Antiviral Candidates against Coxsackievirus A16

    Published on: July 15, 2019

    7.0K
    Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

    Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

    Published on: October 26, 2015

    10.9K

    Related Concept Videos

    Protein-Drug Binding: Mechanism and Kinetics01:16

    Protein-Drug Binding: Mechanism and Kinetics

    Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
    Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
    2.1K
    Enzyme Inhibition01:30

    Enzyme Inhibition

    Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
    72.5K
    Pharmacokinetics: Drug–Drug Interactions01:25

    Pharmacokinetics: Drug–Drug Interactions

    Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
    816
    Factors Affecting Protein-Drug Binding: Drug Interactions01:23

    Factors Affecting Protein-Drug Binding: Drug Interactions

    Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
    Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
    733
    Protein-protein Interfaces02:04

    Protein-protein Interfaces

    Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
    12.6K
    Inhibitors of Viral Protein Synthesis01:30

    Inhibitors of Viral Protein Synthesis

    Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
    73